- 1 Associations of comorbidities and medications with COVID-19
- 2 outcome: A retrospective analysis of real-world evidence data
- 3 Authors
- 4 Basel Abu-Jamous^{1,#}, Arseni Anisimovich^{1,#}, Janie Baxter¹, Lucy Mackillop^{1,2,3}, Marcela P.
- 5 Vizcaychipi^{4,5}, Alex McCarthy⁴, Rabia T. Khan^{1,*}
- 6 Affiliations
- ¹Sensyne Health plc, Schrodinger Building, Heatley Road, Oxford Science Park, Oxford,
- 8 OX4 4GE.
- ²Oxford University Hospitals NHS Foundation Trust, Women's Centre, John Radcliffe
- Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK.
- ³Nuffield Department of Women's and Reproductive Health, University of Oxford, Women's
- 12 Centre, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK.
- 13 ⁴Chelsea and Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London,
- 14 SW10 9NH, UK.
- 15 ⁵Academic Department of Anaesthesia & Intensive Care Medicine, Imperial College London,
- 16 Chelsea & Westminster Campus, 369 Fulham Road, London, SW10 9NH, UK.
- 18 # Joint first author

17

- 19 * Corresponding author
- 20 Correspondence address
- 21 Rabia Tahir Khan
- 22 Sensyne Health plc, Schrodinger Building, Heatley Road, Oxford Science Park, Oxford,
- 23 OX4 4GE
- 24 Email: rabia.khan@sensynehealth.com
- 25 Keywords
- 26 COVID-19, electronic healthcare records, comorbidities, medications, mortality
- 27 Running title
- 28 Associations of comorbidities and medications with COVID-19 outcome

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background Hundreds of thousands of deaths have already been recorded for patients with the severe acute respiratory syndrome coronavirus (SARS-CoV-2; aka COVID-19). Understanding whether there is a relationship between comorbidities and COVID-19 positivity will not only impact clinical decisions, it will also allow an understanding of how better to define the long-term complications in the groups at risk. In turn informing national policy on who may benefit from more stringent social distancing and shielding strategies. Furthermore, understanding the associations between medications and certain outcomes may also further our understanding of indicators of vulnerability in people with COVID-19 and co-morbidities.

Methods Electronic healthcare records (EHR) from two London hospitals were analysed between 1st January and 27th May 2020. 5294 patients presented to the hospitals in whom COVID status was formally assessed; 1253 were positive for COVID-19 and 4041 were negative. This dataset was analysed to identify associations between comorbidities and medications, separately and two outcomes: (1) presentation with a COVID-19 positive diagnosis, and (2) inpatient death following COVID-19 positive diagnosis. Medications were analysed in different time windows of prescription to differentiate between short-term and long-term medications. All analyses were done with controls (without co-morbidity) matched for age, sex, and number of admissions, and a robustness approach was conducted to only accept results that consistently appear when the analysis is repeated with different proportions of the data.

Results We observed higher COVID-19 positive presentation for patients with hypertension (1.7 [1.3-2.1]) and diabetes (1.6 [1.2-2.1]). We observed higher inpatient COVID-19 mortality for patients with hypertension (odds ratio 2.7 [95% CI 1.9-3.9]), diabetes (2.2 [1.4-3.5]), congestive heart failure (3.1 [1.5-6.4]), and renal disease (2.6 [1.4-5.1]). We also observed an association with reduced COVID-19 mortality for diabetic patients for whom anticoagulants (0.11 [0.03-0.50]), lipid-regulating drugs (0.15 [0.04-0.58]), penicillins (0.20 [0.06-0.63]), or biguanides (0.19 [0.05-0.70]) were administered within 21 days after their positive COVID-19 test with

59

60

61

62

63

64

65

66

67

68

no evidence that they were on them before, and for hypertensive patients for whom anticoagulants (0.08 [0.02-0.35]), antiplatelet drugs (0.10 [0.02-0.59]), lipid-regulating drugs (0.15 [0.05-0.46]), penicillins (0.14 [0.05-0.45]), or angiotensin-converting enzyme inhibitors (ARBs) (0.06 [0.01-0.53]) were administered within 21 days post-COVID-19-positive testing with no evidence that they were on them before. Moreover, long-term antidiabetic drugs were associated with reduced COVID-19 mortality in diabetic patients (0.26 [0.10-0.67]).

Conclusions We provided real-world evidence for observed associations between COVID-19 outcomes and a number of comorbidities and medications. These results

require further investigation and replication in other data sets.

Introduction

69

70

71

72

73

74

75

76

77

78

83

84

85

86

87

As of the 16th of August 2020, the COVID-19 pandemic has resulted in more than 770,000 deaths worldwide over the course of a few months. Although most of the confirmed cases of COVID-19 infection show mild or no symptoms, a global concern exists in ensuring that healthcare systems can cope with those that require hospitalisation, especially with the coming winter pressure and while preparing for a potential second wave. Correct identification of individuals with higher risk of presentation or of death due to COVID-19 will not only help hospitals better identify those in need of hospitalisation but will also assist the community in identifying the

Hypertension and diabetes have been shown to be associated with poorer outcome in COVID-19. (Perico, et al., 2020). Furthermore, it has been postulated that certain medications may modulate the immune response to COVID-19 infection, positively or negatively.

We have set out to investigate the association of comorbidities and medications with either presentation with COVID-19 positive diagnosis or death due to COVID-

19 in a real-world-evidence (RWE) dataset.

vulnerable who require more careful shielding.

Methods

The dataset

- 88 Electronic health record (EHR) data were obtained from the Chelsea & Westminster
- 89 Hospital NHS Foundation Trust for 5294 patients presented to the Trust's
- 90 hospitals between 1st January and 27th May 2020. The patient population consisted
- 91 of 1253 COVID-19 positive and 4041 COVID-19 negative patients as diagnosed
- 92 using viral PCR from swap tests.
- 93 For these 5294 patients the dataset included patients' history of primary and
- 94 secondary diagnoses recorded in the hospital (from 2004 to 2020) medications
- administered or prescribed in the hospital (from 2010 to 2020), and death status.

Association analysis of comorbidities with COVID-19 presentation and mortality

We examined the association of comorbidities with COVID-19 positive presentation as well as with inpatient mortality of COVID-19 patients. This is realised by using Fisher's exact test to compare the outcomes of patients with a given comorbidity (the active arm) and patients without that comorbidity (the control arm). To account for possible confounders, the two arms were matched on age, sex, and the number of admissions of patients in their available history (Figure 1 (b)). To reduce false discoveries, multiple hypothesis testing was conducted using the Benjamini Hochberg (BH) method. Furthermore, a robustness analysis was carried out by running the same test experiment once with 100% of the available data and 20 more times with randomly selected proportions (60%, 70%, 80%, or 90%) of the data. An association is considered significant if its adjusted p-value was smaller than 0.05 in more than 70% of these individual experiments (Figure 1 (a)).




Figure 1. Statistical analysis pipeline. (a) For each tested comorbidity or medication, a total of 21 tests of association are conducted with different proportions of the dataset. The tested association is considered significant if $p \le 0.05$ in more than 70% of the tests. (b) Each line of analysis is conducted on active and control arms that are matched on age, sex, and number of admissions. Odds-ratios (OR) and 95% confidence intervals (CI) are calculated only if the active arm included more than 10 patients; otherwise, the test yields no result.

Patients are included in the active arm if a record of the given disease appears at least once in their available history. Disease diagnoses are recorded in our data using the International Classification of Diseases, tenth revision (ICD-10) codes. ICD-10 codes were translated into 19 disease groups following the approach

proposed by (Quan, et al., 2005) with some amendments ensuring that hypertension and asthma were individually assessed in the analysis (Table 1).

Table 1. ICD-10 codes used for comorbidity grouping from (Quan, et al., 2005)*

122

123

124

125

126

127

128

129

130

131

Disease group	ICD-10 codes
Myocardial infarction	121, 122, 1252
Congestive heart failure	143, 150, 1099, 1110, 1130, 1132, 1255, 1420, 1425, 1426, 1427, 1428, 1429, P290
Peripheral vascular disease	170, 171, 1731, 1738, 1739, 1771, 1790, 1792, K551, K558, K559, Z958, Z959
Cerebrovascular disease	G45, G46, I60, I61, I62, I63, I64, I65, I66, I67, I68, I69, H340
Dementia	F00, F01, F02, F03, G30, F051, G311
Chronic pulmonary	J40, J41, J42, J43, J44, J46, J47, J60, J61, J62, J63, J64, J65, J66, J67, I278,
disease excluding asthma*	l279, J684, J701, J703
Asthma*	J45
Connective tissue disease	M05, M32, M33, M34, M06, M315, M351, M353, M360
rheumatic disease	
Peptic ulcer disease	K25, K26, K27, K28
Mild liver disease	B18, K73, K74, K700, K701, K702, K703, K709, K717, K713, K714, K715, K760,
	K762, K763, K764, K768, K769, Z944
Diabetes	E100, E101, E106, E108, E109, E110, E111, E116, E118, E119, E120, E121,
	E126, E128, E129, E130, E131, E136, E138, E139, E140, E141, E146, E148,
	E149, E102, E103, E104, E105, E107, E112, E113, E114, E115, E117, E122,
	E123, E124, E125, E127, E132, E133, E134, E135, E137, E142, E143, E144,
	E145, E147
Paraplegia and hemiplegia	G81, G82, G041, G114, G801, G802, G830, G831, G832, G833, G834, G839
Renal disease	N18, N19, N052, N053, N054, N055, N056, N057, N250, I120, I131, N032,
	N033, N034, N035, N036, N037, Z490, Z491, Z492, Z940, Z992
Metastatic carcinoma	C77, C78, C79, C80
Cancer	C00, C01, C02, C03, C04, C05, C06, C07, C08, C09, C10, C11, C12, C13, C14,
	C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C30, C31, C32,
	C33, C34, C37, C38, C39, C40, C41, C43, C45, C46, C47, C48, C49, C50, C51,
	C52, C53, C54, C55, C56, C57, C58, C60, C61, C62, C63, C64, C65, C66, C67,
	C68, C69, C70, C71, C72, C73, C74, C75, C76, C81, C82, C83, C84, C85, C88,
	C90, C91, C92, C93, C94, C95, C96, C97
Moderate or severe liver	K704, K711, K721, K729, K765, K766, K767, I850, I859, I864, I982
disease	
Aids (HIV)	B20, B21, B22, B24
Hypertension*	10, 11, 12, 13, 15

^{*} These disease groups have been changed from what is proposed in (Quan, et al., 2005). The two changes are splitting the "Chronic pulmonary disease" group into "Chronic pulmonary disease excluding asthma" and "Asthma" and adding the "Hypertension" group.

Analysis of association of medications with COVID-19 presentation and mortality

We investigated the association of pharmacological therapy with COVID-19 positive presentation and inpatient mortality in COVID-19 patients. To assess the association of a given medication with these end points, we utilised the same stringent statistical approach that was described above for the comorbidities analysis, including matching on age, sex, and number of admissions, as well as the robustness analysis with different proportions of the full dataset (Figure 1). However, two further aspects were considered in this analysis; the first was conditioning on comorbidities; that is, the association of each medication with end

points was assessed separately for patients with different comorbidities (Figure 2). This is to reduce the possibility of confounding observed association of medications with outcomes by their association with diseases. The definitions of comorbidity ICD-10 codes were based on Table 1.




Figure 2. Analysis of medications was performed after conditioning on comorbidities.

The second aspect was the incorporation of the time of prescription. This is because the effects of medications can be dependent on the time of admission. Figure 3 illustrates the six lines of analysis that were conducted separately for each medication conditioned on comorbidities. The lines of analysis were designed to handle short-term and long-term medications differently. We define a short-term medication as a medication that was prescribed to the patient within the short period of time of indicated in Figure 3 but never before that (Figure 3: PP-ST1, PP-ST2, M-ST1, and M-ST2). As for long-term medications, they are defined as those which were prescribed at least twice in the patient history, one of which is more recent (Figure 3: PP-LT and M-LT). In all of these lines of analysis, medications with no more than ten patients in their active arm were skipped.

Medications were encoded using British National Formulary (BNF) codes. BNF codes form a hierarchy where medications are classified into *BNF chapters*, which are sub-classified into *BNF sections*, which in turn are classified into *BNF paragraphs*, and so on up to eight levels of depth. In most of the cases, medications in our dataset are recorded with codes up to three or four levels of depth. When counting data records of a given BNF code, all medications of codes in deeper hierarchy levels are counted as well.




Figure 3. Lines of analysis of medications' association with COVID-19 positive presentation or inpatient mortality in COVID-19 patients. The identifiers (IDs) for these lines of analysis are coded by a reference to the considered end point (PP: COVID-19 positive presentation; M: mortality) and a reference to the temporal consideration of the tested medications (ST: short-term; LT: long-term). If two lines of analysis share the same end point and temporal consideration, they are numbered with ordinal numbers.

Results

Characteristics of the dataset

Figure 4 shows that the COVID-19 positive cohort has higher median age, more males, and patients with more hospital admissions than the COVID-19 negative cohort. A similar trend also appears in the cohort of deceased COVID-19 patients compared to the cohort of COVID-19 patients with no observed death in hospital (Figure 4).




Figure 4. Distributions of age (a, b), sex (c, d), and number of admissions in patient's history (e, f), each in COVID-19 positive versus negative patients (a, c, e), and in COVID-19 positive deceased versus survived patients (b, d, f). Calculation of p values was done using the unpaired two-sided Wilcoxon rank-sum test for age and number of admissions distributions (a, b, e, f), and using the two-sided Fisher's exact test for sex distribution (c, d).

Association of comorbidities with COVID-19 presentation and mortality

We observed that the comorbidities of hypertension and diabetes have statistically significant associations with the diagnosis of COVID-19 (Table 2). Moreover, hypertension, diabetes, congestive heart disease, and renal disease show significant association with higher inpatient mortality in COVID-19 patients (Table 3). These results were obtained after controlling for the effect of age, sex, and number of admissions in patients' history.

Table 2. Comorbidity association with presentation with COVID-19 positive diagnosis

		ot have ease	Have disease			
Disease group	CODIV-19 Negative	COVID-19 Positive	CODIV-19 Negative	COVID-19 Positive	$\widetilde{OR}(\widetilde{CI})^*$	POSE#
Hypertension	703	280	606	377	1.66 (1.33-2.07)	90%
Diabetes	339	183	294	228	1.55 (1.16-2.07)	71%
Dementia	126	66	112	80	1.52 (0.94-2.47)	14%
Cancer	120	84	143	61	0.61 (0.38-0.97)	10%
Chronic pulmonary disease excluding asthma	150	113	177	86	0.74 (0.49-1.12)	5%
Congestive heart failure	156	86	158	84	0.91 (0.59-1.40)	0%
Asthma	197	102	192	107	1.12 (0.76-1.66)	0%
Mild liver disease	91	27	89	29	0.73 (0.38-1.42)	0%
Connective tissue disease rheumatic disease	42	15	40	17	1.27 (0.48-3.34)	0%
Peptic ulcer disease	50	29	52	27	0.98 (0.46-2.08)	0%
Paraplegia and hemiplegia	50	27	51	26	0.86 (0.40-1.85)	0%
Renal disease	145	105	151	99	0.95 (0.63-1.44)	0%
Peripheral vascular disease	81	31	74	38	1.04 (0.54-1.99)	0%
Metastatic carcinoma	44	24	51	17	0.57 (0.24-1.34)	0%
Cerebrovascular disease	146	103	161	88	0.85 (0.56-1.29)	0%
Myocardial infarction	140	99	160	79	0.74 (0.48-1.14)	0%
Moderate or severe liver disease ^{\$}	Low number ^{\$}	Low number ^{\$}	Low number ^{\$}	Low number ^{\$}	NA ^{\$}	NA ^{\$}
Aids (HIV) ^{\$}	Low number ^{\$}	Low number ^{\$}	Low number ^{\$}	Low number\$	NA ^{\$}	NA ^{\$}

 $^{{}^*\}widetilde{OR}$ is the geometric mean of the odds ratios obtained from the 21 robustness experiments run with different proportions of data as demonstrated in Figure 1 (a). \widetilde{CI} is the 95% confidence interval where its limits were calculated using the geometric means of the CI limits of the aforementioned 21 robustness experiments. # POSE: the percentage of significant experiments; that is, the percentage of experiments run over different proportions of data that yielded a significant p-value of 0.05 or smaller. This is a measure of robustness. \$ Very small numbers of patients were available for these comorbidities and therefore statistics are not applicable (NA).

Table 3. Comorbidity association with mortality of COVID-19 positive patients

		not have ease	Have disease			
Disease group	Survived	Deceased	Survived	Deceased	$\widetilde{OR}\left(\widetilde{CI}\right)^{\star}$	POSE#
Hypertension	294	83	214	163	2.70 (1.87-3.92)	100%
Diabetes	176	52	127	101	2.20 (1.38-3.49)	95%
Congestive heart failure	57	27	35	49	3.05 (1.45-6.41)	81%
Renal disease	61	38	40	59	2.63 (1.35-5.13)	76%
Cerebrovascular disease	59	29	44	44	2.09 (1.02-4.29)	38%
Myocardial infarction	47	32	35	44	2.13 (1.01-4.49)	24%
Peripheral vascular disease	27	11	17	21	3.29 (1.04-10.4)	19%
Dementia	47	33	35	45	1.89 (0.90-3.96)	14%
Metastatic carcinoma	10	7	5	12	4.56 (0.79-26.3)	10%
Cancer	36	25	31	30	1.61 (0.69-3.76)	5%
Peptic ulcer disease	16	11	14	13	1.61 (0.44-5.87)	5%

Chronic pulmonary disease excluding asthma	46	40	43	43	1.65 (0.81-3.36)	0%
Asthma	73	34	69	38	1.20 (0.62-2.32)	0%
Mild liver disease	22	7	20	9	1.04 (0.27-3.98)	0%
Paraplegia and hemiplegia	16	10	16	10	1.50 (0.38-5.88)	0%
Connective tissue disease rheumatic disease	10	7	12	5	0.57 (0.10-3.24)	0%
Moderate or severe liver disease [§]	Low number ^{\$}	Low number ^{\$}	Low number ^{\$}	Low number ^{\$}	NA ^{\$}	NA ^{\$}
Aids (HIV) ^{\$}	Low number ^{\$}	Low number ^{\$}	Low number ^{\$}	Low number ^{\$}	NA ^{\$}	NA ^{\$}

^{*} \widetilde{OR} is the geometric mean of the odds ratios obtained from the 21 robustness experiments run with different proportions of data as demonstrated in Figure 1 (a). \widetilde{CI} is the 95% confidence interval where its limits were calculated using the geometric means of the CI limits of the aforementioned 21 robustness experiments. # POSE: the percentage of significant experiments; that is, the percentage of experiments run over different proportions of data that yielded a significant p-value of 0.05 or smaller. This is a measure of robustness. \$ Very small numbers of patients were available for these comorbidities and therefore statistics are not applicable (NA).

Association of medications with COVID-19 presentation and mortality

Table 4 shows the numbers of medications qualified for testing in each line of analysis given that they were prescribed to more than 10 patients within the relevant time window (Figure 3). This table also shows the number of medications, out of all of those qualified for testing, that showed significant and robust association with reduced presentation with COVID-19 (lines PP-ST1, PP-ST2, and PP-LT) or with reduced inpatient mortality in COVID-19 patients (lines M-ST1, M-ST2, and M-LT).

Table 4. Summary of numbers of medications qualified for testing in each one of the six lines of analysis and numbers of medications with significant association with reduced COVID-19 positive presentation or with reduced mortality in COVID-19 patients.

	Medications qualithose with mo active arm)			Medications associated with reduced COVID-19 positive presentation (PP- lines) or with reduced mortality (M- lines)			
Line of analysis ID	BNF Sections	BNF paragraphs	BNF sub- paragraphs	BNF Sections BNF BNF sub- paragraphs paragraphs			
PP-ST1	21	18	5	0	0	0	
PP-ST2	22	19	5	0	0	0	
PP-LT	112	53	10	0	0	0	
M-ST1	53	37	10	10	7	2	
M-ST2	50	36	10	11	6	1	
M-LT	60	27	5	1	0	0	

None of the tested medications was significantly and robustly associated with reduced COVID-19 presentation in our results, whether while considering short-term medications (PP-ST1 and PP-ST2) or long-term medications (PP-LT). Results with different thresholds of robustness are provided in Supplementary File S1.

Table 5. Statistically significant and robust associations between medications and mortality for COVID-19+ patients. The full list of tested medications is included in Supplementary File S1.

		Not on M	edication	On Med	dication		
Disease group	Drug BNF code / drug name	Survived	Deceased	Survived	Deceased	$\widetilde{OR}(\widetilde{CI})^*$	POSE#
	Inters	ection of N	I-ST1 and N	И-ST2 ^{\$}			
Diabetes	02.08.02	72	96	21	3	0.11 (0.03-0.50)	100%
	Oral Anticoagulants						
	02.12	70	90	22	4	0.15 (0.04-0.58)	86%
	Lipid-Regulating Drugs						
	05.01.01.03	73	94	24	5	0.20 (0.06-0.64)	90%
	Broad-Spectrum Penicillins						
	06.01.02.02	74	94	19	4	0.19 (0.05-0.70)	81%
	Biguanides						
Hypertension	01.03	120	148	31	9	0.22 (0.09-0.56)	100%
	Antisecretory Drugs+Mucosal						
	Protectants				_		
	01.06	129	153	21	3	0.10 (0.02-0.45)	95%
	Laxatives						
	02.05.05.01	140	160	17	1	0.06 (0.01-0.53)	81%
	Angiotensin-Converting Enzyme						
	Inhibitors				_	2 (2 (2 2 4 2 2 2)	10001
	02.06.02	122	154	33	5	0.12 (0.04-0.36)	100%
	Calcium-Channel Blockers				_		
	02.08.01	144	160	19	2	0.09 (0.02-0.50)	90%
	Parenteral Anticoagulants					2 22 (2 22 2 27)	10001
	02.08.02	122	153	27	3	0.08 (0.02-0.35)	100%
	Oral Anticoagulants				_		
	09.02	139	158	16	2	0.10 (0.02-0.59)	95%
	Antiplatelet Drugs					2 (5 (5 5 5 5 (6)	
	02.12	118	148	33	6	0.15 (0.05-0.46)	95%
	Lipid-Regulating Drugs	100	450	10	_	2 22 (2 27 2 22)	700/
	04.07.01	136	152	19	5	0.22 (0.07-0.69)	76%
	Non-Opioid Analgesics And						
	Compound Prep	101	150	00	_	0.44 (0.05.0.45)	1000/
	05.01.01.03	131	156	29	5	0.14 (0.05-0.45)	100%
	Broad-Spectrum Penicillins						
	M-ST1 other th			eared in M	I-ST2		
		No	one				
	M-ST2 other the	an those th	at also app	eared in M	I-ST1		
Diabetes	02.05	79	92	14	3	0.15 (0.03-0.66)	71%
	Hypertension and Heart Failure						
	02.06	79	96	14	2	0.11 (0.02-0.60)	86%
	Nit,Calc Block & Other					,	
	Antianginal Drugs						
Hypertension	02.02	134	151	21	8	0.33 (0.12-0.91)	81%
	Diuretics						
	02.04	134	152	19	7	0.29 (0.10-0.86)	86%
	Beta-Adrenoceptor Blocking						
	Drugs						
		M	-LT				
Diabetes	06.01	30	65	26	12	0.26 (0.10-0.67)	71%
	Drugs Used In Diabetes						

 $^{{}^*\}widetilde{OR}$ is the geometric mean of the odds ratios obtained from the 21 robustness experiments run with different proportions of data as demonstrated in Figure 1 (a). \widetilde{CI} is the 95% confidence interval where its limits were calculated using the geometric means of the CI limits of the aforementioned 21 robustness experiments.

[#] POSE: the percentage of significant experiments; that is, the percentage of experiments run over different proportions of data that yielded a significant p-value of 0.05 or smaller. This is a measure of robustness.

^{\$} Medications of significant association with reduced mortality in both M-ST1 and M-ST2. Numbers of patients as well as \widetilde{OR} and \widetilde{CI} values shown in this table are as reported in the results of the M-ST2 line.

- 201 Table 5 lists medications that passed the test of robust statistical significance.
- 202 Where a BNF section and one of its BNF paragraphs both appear significant, the
- 203 one that is less specific is omitted from this table for a more concise display.
- Nonetheless, all tested medications are listed in Supplementary File S2.
- 205 Considering short-term medications (M-ST1 & M-ST2), we observed an association
- with lower COVID-19 mortality for both diabetic and hypertensive patients for whom
- 207 anticoagulants, lipid-regulating drugs, and penicillins were administered after their
- 208 positive COVID-19 test (Table 5).
- 209 Biguanides prescribed to diabetic patients after testing positive on COVID-19 were
- 210 associated with reduced mortality (Table 5). Interestingly, the more general BNF
- 211 section of drugs used in diabetes, which includes insulins as well as antidiabetic
- 212 drugs, showed association with reduced COVID-19 mortality for diabetic patients
- 213 for whom there is an evidence of prescription before and after a positive COVID-19
- 214 test (M-LT) (Table 5).
- 215 Furthermore, angiotensin-converting enzyme inhibitors (ARBs) and antiplatelet
- 216 drugs showed association with reduced COVID-19 mortality when administered to
- 217 hypertensive patients after testing positive on COVID-19 (M-ST1 & M-ST2) (Table 5).

218 Discussion

- 219 We describe the retrospective analysis of 5294 patients presenting to two hospitals
- 220 in London; 1253 of whom were COVID-19 positive. We observe that having a
- 221 diagnosis of hypertension or diabetes was associated with a higher presentation
- with COVID-19, and that hypertension, diabetes, congestive heart failure, and renal
- 223 disease were associated with a higher chance of in-hospital death for COVID-19
- 224 positive patients. Furthermore, we observe associations between a number of
- 225 medications prescribed after a positive COVID-19 test and reduced mortality;
- 226 examples include anticoagulants, lipid-regulating drugs, and penicillins for diabetic
- 227 and hypertensive patients, biguanides for diabetic patients, and ARBs and
- 228 antiplatelets drugs for hypertensive patients. We also observed an association with

reduced COVID-19 mortality for diabetic patients who have been on diabetic drugs even before testing positive on COVID-19.

Co-morbidities associated with COVID-19 have been reported previously in the literature for a number of diseases such as hypertension (Williams & Zhang, 2020; Vizcaychipi, et al., 2020), renal diseases, and diabetes (Wu & McGoogan, 2020; Chen, et al., 2020; Yang, et al., 2020; Wang, et al., 2020; Perico, et al., 2020; Vizcaychipi, et al., 2020). COVID-19 patients with such co-morbidities were more likely to present to hospital which is in line with many NHS triage systems who recognise this group as vulnerable and therefore are more likely to recommend hospital attendance.

Some of our observations of associations of medications are in-line with published literature, such as the protective effect of anticoagulants patients on COVID-19 outcomes (Atallah, et al., 2020; Tang, et al., 2020). On the other hand, some of our observations on medications were at odds with the published literature or published literature gave conflicting results, such as the effect of ARBs (Perico, et al., 2020;

244 Cure & Cure, 2020a; Cure & Cure, 2020b).

For all lines of analyses of comorbidities and medications, matching active and control arms on age, sex, and number of admissions was essential to account for substantial confounding factors. The essence of this is indicated by observing that the distributions of these covariates differed significantly between patients who had positive and negative COVID-19 test results as well as between COVID-19 patients who died and who did not (Figure 4). Matching the number of hospital admissions aims at comparing patients with more comparable medical history and overall health condition.

Limitations

Observed associations should be interpreted with care as they might be attributable to confounding factors. For example, we did not use measures of functional status, e.g. clinical fragility scale, which may have been over-represented in one arm of our analysis. Furthermore, we have not considered interactions between multiple co-

morbidities and their association with outcomes. Severity of COVID-19 infection at presentation was not incorporated and no distinction is being made in this analysis between those who have been admitted for an acute episode of some comorbidity in their most recent admission and those who have not despite having that condition chronically. Also, length of symptoms at point of presentation to hospital were not assessed neither was the frailty scale.

Observations in this study are based on a population of patients presenting to hospitals and for whom COVID-19 status has been assessed to be positive or negative. This may cause a bias as it is not comparing individuals belonging to the general community population. Also, this population of patients comes from two London metropolitan hospitals that may not have a similar distribution of comorbidities and features as hospitals in other metropolitan cities or hospitals away from large cities. Generalisability is therefore not assured without further confirmatory studies. Additionally, our data does not include medications prescribed in primary care, resulting in a potentially inaccurate representation of the medication history of patients, especially prior to having a positive COVID-19 test result.

- Finally, low data coverage and bias may cause absence of statistically significant associations with COVID-19 outcomes for some comorbidities or medications. Therefore, no conclusions may be drawn for such cases without further investigation.
- Conclusions

This study provides an important piece of real-world evidence on associations between co-morbidities and medication prescription, respectively with COVID-19 positivity presenting to hospital and inpatient mortality. Identifying these associations can help in the crucial task of defining the vulnerable groups that may benefit from more stringent social distancing especially as lockdown due to COVID-19, is relaxed. Nonetheless, observations in this study have to be interpreted with caution due to potential bias and confounders, and confirmatory studies will be required to draw reliable conclusions.

Acknowledgements 288 289 This work uses data provided by patients and collected by the NHS as part of their 290 care and support. We believe using patient data is vital to improve health and care 291 for everyone and would, thus, like to thank all those involved for their contribution. 292 Special thanks are due to the Chelsea and Westminster (CW) COVID-19 AICU 293 Consortium, comprising all critical care personnel who were part of the delivery of 294 care during the COVID444 19 pandemic as follows: CW Anaesthetics Consultants. 295 Critical Care Consultants, Trainees & Fellows from ICU, Anaesthesia, and seconded 296 to ICU from other specialities, Surgeons, the supporting Respiratory and ED 297 Physicians, Operating Department Practitioners and CW Critical Care Nurses. This 298 united approach to an unprecedented clinical condition was critical not only to the 299 management of the patients but also to our ability to document and collate the key 300 data in a timely manner to support this analysis. 301 Also, a special thank you to Trystan Hawkin, Chris Chaney from CWplus, the 302 Planned Care Clinical Division managers, porters, domestic personnel and the CW 303 local community who without hesitation have supported the National Healthcare 304 System throughout the COVID-19 pandemic. Compliance with ethical guidelines 305 306 All methods were performed in accordance with the relevant guidelines and 307 regulations. 308 The study was approved by the IG management team of Sensyne Health plc and 309 Chelsea & Westminster NHS Foundation Trust under the Strategic Research 310 Agreement (SRA) and relative Data Sharing Agreements (DSAs) signed by the NHS 311 Trust and Sensyne Health plc on 25th July 2018. 312 All analyses were conducted on data with no personal identifying information. 313 Therefore, informed consent was waived by the ethics committee of the Chelsea & 314 Westminster NHS Foundation Trust, which provided ethical approval for the study.

315	References
316 317	Atallah, B., Mallah, S. I. & AlMahmeed, W., 2020. Anticoagulation in COVID-19. European Heart Journal - Cardiovascular Pharmacotherapy, p. pvaa036.
318 319	Chen, T. et al., 2020. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. <i>BMJ</i> , Volume 368, p. m1091.
320 321 322	Cure, E. & Cure, M. C., 2020a. Comment on "Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade". <i>Nephron Clinical Practice</i> , Volume 144, pp. 251-252.
323 324 325 326	Cure, E. & Cure, M. C., 2020b. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. <i>Diabetes & Metabolic Syndrome: Clinical Research & Reviews</i> , 14(4), pp. 349-350.
327 328 329	Perico, L., Benigni, A. & Remuzzi, G., 2020. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. <i>Nephron Clinical Practice</i> , pp. 1-9.
330 331	Quan, H. et al., 2005. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data. <i>Medical Care</i> , 43(11), pp. 1130-1139.
332 333 334	Tang, N. et al., 2020. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. <i>Journal of Thrombosis and Haemostasis</i> , 18(5), pp. 1094-1099.
335 336 337 338	Vizcaychipi, M. P. et al., 2020. Increase in COVID-19 inpatient survival following detection of Thromboembolic and Cytokine storm risk from the point of admission to hospital by a near real time Traffic-light System (TraCe-Tic). The Brazilian Journal of Infectious Diseases, In Press(10.1016/j.bjid.2020.07.010).
339 340 341	Wang, Kw.et al., 2020. Epidemiology of 2019 novel coronavirus in Jiangsu Province, China after wartime control measures: A population-level retrospective study. <i>Travel Medicine and Infectious Disease.</i>
342 343	Williams, B. & Zhang, Y., 2020. Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19. <i>LANCET</i> , 395(10238), pp. 1671-1673.

344	Wu, Z. & McGoogan, J. M., 2020. Characteristics of and Important Lessons From
345	the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA, 323(12)
346	pp. 1239-1242.
347	Yang, J. et al., 2020. Prevalence of Comorbidities and Its Effects in Patients
348	Infected With SARS-CoV-2: A Systematic Review and Meta-Analysis. Int J
349	Infect Dis., Volume 94, pp. 91-95.
350	